Skip to main
BLFS

BioLife Solutions (BLFS) Stock Forecast & Price Target

BioLife Solutions (BLFS) Analyst Ratings

Based on 5 analyst ratings
Hold
Strong Buy 0%
Buy 0%
Hold 100%
Sell 0%
Strong Sell 0%

Bulls say

BioLife Solutions is projected to see strong revenue and earnings growth in the current and upcoming year as demand for its biopreservation products, particularly CryoStor, continues to increase. The recent acquisition by Repligen is a strategic move that is seen as the best path forward for BioLife Solutions, given Repligen's scale, commercial reach, and commitment to the cell and gene therapy industry. While the proposed acquisition now largely defines the investment case, BioLife's differentiated position in biopreservation and its exposure to the growing field of cell and gene therapy remain positive factors for future growth and profitability.

Bears say

BioLife Solutions is a life sciences company that provides biopreservation products and services for the cell and gene therapy industry. The company has experienced strong growth in the second quarter of 2026, with revenues increasing 21% year-over-year and adjusted operating income reaching $3.1 million. However, there is uncertainty surrounding the company's future as it is currently in the process of being acquired by Repligen, and the stock is likely to be primarily driven by transaction developments and Repligen's performance until the deal is finalized. As such, a "Hold" rating is appropriate at this time.

BioLife Solutions (BLFS) has been analyzed by 5 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 0% recommend Buy, 100% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BioLife Solutions and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BioLife Solutions (BLFS) Forecast

Analysts have given BioLife Solutions (BLFS) a Hold based on their latest research and market trends.

According to 5 analysts, BioLife Solutions (BLFS) has a Hold consensus rating as of Sep 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $31, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $31, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BioLife Solutions (BLFS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.